Purpose: Germ cell tumors (GCTs) represent the most frequent malignancies among young men, but little is known about circulating tumor cells (CTCs) in these tumors. Considering their heterogeneity, CTCs were investigated using two independent assays targeting germ cell tumor and epithelial cell-specific markers, and results were correlated with disease stage, histology, and serum tumor markers.
Introduction
Germ cell tumors (GCTs) of testis are the most frequent malignancies in young men between the ages of 20 and 40 years. Less than 10% of all GCTs arise in extragonadal sites (e.g., mediastinum); however, their management follows that of testicular GCTs (1) . The incidence of GCTs in Western countries is increasing since decades (2) . The available serum tumor markers-a-fetoprotein (AFP), b-human chorionic gonadotropin (bHCG), and lactate dehydrogenase (LDH)-used for diagnostics and follow-up are increased in up to 80% of patients with testicular GCTs (3) . However, these markers are not elevated in patients with pure teratoma. The gold standard for detecting metastases is computed tomography of the chest, abdomen, and pelvis. However, approximately 10% to 20% and 30% of patients with stage I seminomatous and nonseminomatous testicular GCTs, respectively, have occult (invisible at the time of diagnosis) metastases, leading to relapse during surveillance (4, 5) . Therefore, additional markers would facilitate staging and clinical decision-making.
Detection of circulating tumor cells (CTCs) has been associated with poor prognosis in patients with carcinoma (6) (7) (8) . However, little is known about the presence of CTCs in blood of patients with GCTs. Few studies have previously assessed presence of tumor-specific mRNA or whole cells in apheresis products of patients undergoing peripheral stem cell transplants (9) (10) (11) . In addition, in a small number of studies, putative CTCs in peripheral blood of patients with testicular GCTs were detected by reverse transcriptase PCR (RT-PCR) using AFP and human chorionic gonadotropinspecific mRNA as markers (12, 13) .
In the present study, we developed a new assay using a label-free enrichment method based on physical properties of tumor cells (i. e., Ficoll density centrifugation) and including both epithelial cell markers (keratins 8, 18, 19 and EpCAM) and germ cell-specific markers (SALL4 and OCT3/4) for CTC detection in patients with GCTs. Histologically, human GCTs can be divided into seminomas, which resemble primordial germ cells, and nonseminomas, which are either undifferentiated (embryonal carcinoma) or differentiated, exhibiting different degrees of embryonic (teratoma) or extra-embryonic (yolk sac tumor and choriocarcinoma) patterning (14) . Sal-like protein 4 (SALL4), a stem cell marker, has been reported as a novel sensitive and specific diagnostic marker that is present in all testicular GCT types (15) . OCT3/4 (POU5F1) is a transcription factor involved in regulation of pluripotency during normal development and is a sensitive and specific marker for seminomas and embryonal carcinomas (16) . Keratins 8 and 18 are the keratins of simple epithelia. These are the first 2 keratins expressed during mouse embryogenesis and might be expressed by seminomas and embryonal carcinomas (17) (18) (19) (20) . Keratin 19 as a marker for epithelial cells was found to be present in some seminomas and the majority of nonseminomas (10) . Furthermore, EpCAM is a homophilic, calcium-independent cell adhesion molecule and is uniquely expressed in germline and spermatogonial stem cells (21, 22) . Sch€ onberger and colleagues showed that EpCAM is highly expressed in malignant GCTs such as yolk sac tumors and choriocarcinomas (23) .
In parallel, we applied the semiautomated CellSearch system for CTC detection. This system is thus far the only assay cleared by the U.S. Food and Drug Administration (FDA) for CTC detection, following the pivotal clinical studies in patients with metastatic breast, prostate, and colon cancer (6, 24, 25) . CTCs are captured by EpCAMcoated beads and identified at the single cell level by immunostaining with antibodies against different keratins, including 8, 18, and 19 (26, 27) . To the best of our knowledge, no data has so far been published on the use of the CellSearch system in GCTs.
Thus, the aim of the present study was to determine the incidence of CTCs in patients with GCTs using 2 independent assays and to correlate the findings to clinical parameters such as tumor histology, stage of disease, and tumor marker levels in blood serum.
Materials and Methods

Characteristics of patients
One-hundred and forty-one patients suffering from histologically proven testicular GCTs and 2 patients with mediastinal GCTs were included in this study. Pathologists experienced in GCT pathology evaluated all tumor samples within the clinical routine. All patients were treated between October 2011 and November 2013 in 1 of the 4 participating centers: Department of Urology of the Federal Armed Forces Hospitals, Hamburg and Berlin, Germany; Department of Urology, or Department of Oncology (University Medical Centre Hamburg-Eppendorf, Hamburg, Germany). Blood samples were taken with informed consent after approval by an institutional review board. One-hundred and thirty-seven peripheral blood samples were taken from patients at the time of initial therapy after diagnosis had been established, and 6 patients with GCTs who relapsed after conventional treatment were enrolled (Supplementary Table S1 ). For patients with refractory disease, parameters concerning the primary tumor, except histology of the primary lesion, were not considered. In addition, 19 testicular vein blood (TVB) samples were collected intraoperatively during orchiectomy from patients with testicular GCTs. Nineteen individuals were included as control group, 9 suffering from non-GCTs of the testis (Leydig cell tumor, Sertoli cell tumor) and 10 healthy male volunteers. Detailed clinicopathologic parameters of all patients are summarized in Table 1 . The study was conducted according to REMARK study recommendations (28) .
Control material
To select suitable markers for CTC detection, the expression of different germ and epithelial cell-specific markers was examined in 4 different GCT cell lines-TCam-2 (seminoma), 2102Ep (embryonal carcinoma), NCCIT (malignant pluripotent embryonal carcinoma), NT2 (embryonal carcinoma/teratoma), as well as in 12 histologically different primary testicular tumors. For sensitivity experiments,
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blood samples from healthy donors were spiked with different numbers (50, 100, and 500) of tumor cells from each cell line and processed using Ficoll-Hypaque gradient centrifugation. In addition, 500 cells of all 4 GCT cell lines were titrated into normal peripheral blood and processed in the CellSearch system to assess thresholds for the detection of GCT cells with this system.
Enrichment of CTCs
About 9 to 17 mL of peripheral blood and 0.5 to 3.2 mL of TVB was collected into EDTA tubes. All blood samples were processed within a maximum of 24 hours after collection. Mononuclear cells (MNCs) were enriched using the FicollHypaque gradient centrifugation (29) . The MNC fraction, preferably containing CTCs, was resuspended in 1 mL of 1Â PBS and spinned down to prepare the microscopic slides. The slides were left overnight to air-dry at room temperature and used within 24 hours for further analysis. For long-term storage, slides were wrapped in aluminum foil back to back and stored at À80 C. Finally, all the specimens were counterstained with DAPI VectaShield Medium (Vector Laboratories) and covered with coverslips. Slides were evaluated under the fluorescence microscope (Axioplan2).
Detection of CTCs using the combination of GCTs and epithelial markers
CellSearch analysis of CTCs
In parallel, 122 blood samples (7.5 mL) were collected in CellSave tubes (Veridex). The CellSearch system (Veridex) was used as previously described (8, 27) . All blood samples were measured within 96 hours after collection. Epithelial cells among the cells captured by anti-EpCAM antibodies were detected by binding of antibodies directed against keratins 8, 18, and 19. An anti-CD45 antibody was used to exclude leukocytes. Nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI). After enrichment and immunocytochemical staining, immunomagnetically labeled cells were kept in a strong magnetic field and scanned using the CellSpotter Analyzer (Veridex). Results of the analyses were interpreted by researchers experienced with this system, and CTC assessment was performed on a cell by cell basis.
Evaluation of apoptosis
Apoptotic cells were assessed by characteristic morphology-presence of small pycnotic nuclei or apoptotic bodies 
FISH analysis of CTCs
To confirm the germ cell origin of CTCs, FISH was conducted using a probe derived from the Homo sapiens PAC clone 876C13 from region 12p11.23 (kindly provided by A. J. M. Gills and L. H. J. Looijenga). The probe overlaps the most frequently amplified region in GCTs identified as 12p11.2-p12.1 (30, 31) . Four samples from peripheral and one sample from testicular blood were analyzed. Briefly, cytospins were incubated with denaturation solution (70% formamid, 3% 20Â SCC in distilled water, pH ¼ 7.4) for 5 minutes at 75 C. Slides were dehydrated, and enzyme pretreatment of cells was carried out with Proteinase-K (Boehringer Manheim, diluted to 0.1 mg/mL in 1Â PBS) solution for 7 minutes at 37 C. Cytospins were washed, dehydrated, and air-dried before adding the hybridization probe (10 mL) and labeled with Spectrum Orange-dUTP (Abbott Molecular Inc.) and the centromere 12 probe (1 mL, Spectrum Green, Abbott Molecular Inc.). After denaturation at 75 C for 7 minutes, hybridization was carried out at 37 C overnight. Post-hybridization washes were carried out at 72 C and at room temperature in 2Â SSC/0.3% NP-40 (Zytovision) for 3 minutes each. After dehydration in ascending concentrations of ethanol and air drying, slides were mounted with mounting medium containing DAPI (Vector Laboratories).
Statistical analysis
Statistical analyses were conducted with the usage of SPSS software, ver. 21.0, licensed for the University Medical Centre Hamburg-Eppendorf. Descriptive analyses were conducted using the Fisher exact test for categorical variables. Differences in variables with a continuous distribution across categories were assessed using the MannWhitney U test. Results were considered statistically significant if P < 0.05 and highly statistically significant if P < 0.001.
Results
Expression of selected markers in GCT cell lines and primary tumors
Strong expression of SALL4, OCT3/4, and keratins was found in more than 75% of the cells of all GCT cell lines. In some cells of the TCam-2 and NT2 cell lines, keratins were detected in a dot-like pattern (Supplementary Fig. S1D ). While EpCAM was strongly expressed in TCam-2 and 2102Ep cells, only weak or no expression was observed in NT2 and NCCIT cells (Supplementary Fig. S1A ). Cells from all 4 cell lines were detected by the CellSearch system ( Supplementary Fig. S1B ). All 12 primary tumors showed strong SALL4 and OCT3/4 expression, whereas only 8 (66.7%) of primary tumors exhibited strong or moderate keratin staining, of which 3 (25.0%) showed a dot-like pattern. EpCAM was expressed in 5 (41.6%) of the primary tumors ( Supplementary Fig. S1C ).
Analysis of recovery rates and assay specificity for GCT cell lines
Using Ficoll-Hypaque gradient centrifugation followed by ICC staining with selected markers, tumor cells spiked into blood of healthy donors were recovered in the range of 60% to 70% (data not shown). For the CellSearch system, the recovery rate was 80% to 100% (data not shown).
No positive cells for selected markers (SALL4, OCT3/4, keratins, and EpCAM) were found in the peripheral blood of 10 healthy volunteers or in non-GCT patients (data not shown).
CTCs in peripheral blood
Fourteen (9.8%) of 143 patients were positive for CTCs enriched by Ficoll density gradient centrifugation and detected by subsequent staining with SALL4/keratins and/ or OCT3/4/EpCAM (Fig. 1A) . Fourteen (11.5%) of 122 patients were classified as CTC positive after CellSearch processing (Fig. 1C) . In total, CTCs were found in 25 (17.5%) of 143 patients with GCTs, irrespective of the method. Interestingly, only in 3 patients, CTCs were found in parallel with both detection methods.
The mean number of CTCs enriched by Ficoll density gradient centrifugation was 13 in 3 Â 10 6 of MNCs (range, 2-60; median, 8.5). Using the CellSearch system, the mean number of CTCs was 2.6 per 7.5 mL of blood (range, 1-14; median, 1). CTCs showed heterogeneous staining of selected proteins within individual cells from the same patient (Table 2 ) and in 5 (20.0%) of CTC-positive patients we observed clusters of 3 to 5 cells.
CTCs in TVB
In total, 12 (63.2%) of 19 TVB samples were positive for tumor cells. The mean tumor cell number was 45 (range, 4-120; median, 16) per 1 Â 10 6 of MNCs. In 7 (58.3%) patients, CTCs were forming clusters of 3 to 7 cells (Fig.  1B) . In one patient, CTCs were found both in testicular vein and peripheral blood and no patient had CTCs in peripheral vein only. Because of the small number of samples, no further statistical analysis was done for tumor cells detected in TVB samples.
Detection of gains in 12p chromosomal region of CTCs
In 4 patients, CTCs with gains of the 12p chromosomal region were found in peripheral blood ( Fig. 2B; Table 3 ). In one tested sample from testicular vein, 4 tumor cells with 5 to 12 signals from the 12p region of interest and 5 to 7 centromere 12 signals were found, which was similar to aberrations observed in the primary tumor tissue ( Fig.  2A ; Table 3 ). Leukocytes present on slides showed 2 signals for 12p and centromere 12 each.
Association of CTCs with clinicopathologic parameters
To assess clinical characteristics associated with the detection of CTCs, correlations between the presence of CTCs and different clinicopathologic parameters of patients were analyzed (Table 4) . Regarding histology of the primary tumor, CTCs were more frequently found in patients with nonseminomas than in pure seminomas (Fisher exact test, 2-sided; P < 0.001). Patients positive for CTCs had significantly higher percentages of yolk sac tumor (Mann-Whitney U test; P < 0.001) and teratoma (Mann-Whitney U test; P ¼ 0.004) histologic components within the primary tumor. Not unexpectedly, CTC positivity after CellSearch processing was associated with !50% of embryonal carcinoma component (Fisher exact test, 2-sided; P ¼ 0.002), and CTCs detected by Ficoll enrichment followed by ICC staining showed an association with an increased content of choriocarcinoma component in primary tumors (Mann-Whitney U test; P ¼ 0.037).
The presence of CTCs also correlated with elevated levels of serum tumor markers. Detection of CTCs was significantly associated with elevated levels of AFP (Mann-Whitney U test; P ¼ 0.025), bHCG (Mann-Whitney U test; P ¼ 0.002), and LDH (Mann-Whitney U test; P ¼ 0.002). However, it is noteworthy that 4 patients with normal levels of serum markers were positive for CTCs.
Preliminary follow-up evaluation
The median follow-up time was too short (mean, 13.7 months; range, 0.66-24.1; median, 14.9) for an in-depth analysis of the prognostic relevance of CTCs. However, it is noteworthy that all 6 patients with treatment-refractory disease who were included in this analysis were positive for CTCs. Of these patients, 3 died within less than 3 months after blood collection (Supplementary Table S1 ). In peripheral blood of 1 patient, CTCs were detected using Ficoll enrichment followed by ICC staining, the second patient showed CellSearch positivity, and the third patient was positive by both detection methods.
Discussion
This is the first study demonstrating the presence of CTCs in a large number of patients with GCTs, including all clinical stages and all histologic subtypes. We were able to detect CTCs in approximately 18% of patients with GCTs using immunocytochemical staining with GCT-and epithelial cell-specific markers in 2 independent CTC assays based on different physical capture technologies. Detection of CTCs was correlated to higher tumor stages, more aggressive tumor histology, increased tumor markers in serum, and early relapses, suggesting that CTCs detected by our assays might either contribute to or at least indicate disease progression in GCTs.
Interestingly, there was little overlap between our new assay and the FDA-cleared CellSearch system. In total, only 3 patients were classified as CTC positive by both assays, demonstrating that by the combination of both assays CTC detection in patients with GCTs can be improved. This finding can be explained by the fact that our new assay captures CTCs based on physical properties and adds germ cell markers to the epithelial cell markers used by the CellSearch system, which accommodates the rather complex biology of GCTs (19, 23) . Finding reliable markers for the identification of CTCs in patients with GCTs is challenging because of the high histologic diversity of these tumors comprising both pure seminomas and tumors with different nonseminomatous tumor components. Therefore, these tumors present with very heterogeneous expression patterns of germ cell and epithelial cell-specific proteins. Not surprisingly, the only previously published immunocytochemical CTC analysis in patients with GCTs using the pan-anti-keratin antibody A45-B/B3 only identified 3 of 20 (15%) patients with advanced and/or relapsed GCTs as positive for CTCs (10) . In our study, we performed an immunocytochemical analysis applying a combination of novel germ cellspecific (anti-SALL4, anti-OCT3/4) and epithelial cellspecific (anti-keratin, anti-EpCAM) antibodies. Fourteen patients (9.8%) had CTCs, positive for at least 2 of the selected markers, and the selected marker combination consisting of SALL4, OCT3/4, keratins 8, 18, 19, and EpCAM seems to be sensitive and specific to detect different types of GCTs.
Using FISH, the detected CTCs showed gain of the 12p chromosomal region, which is a cytogenetic hallmark of GCTs present in about 80% of tumors (30, 31) . This finding additionally confirms the germ cell origin of CTCs and thus specificity of our assays.
To investigate whether the detection of CTCs in patients with GCTs is associated with an increased risk of metastatic relapse and progression, as shown for other tumor entities (32, 33) , future long-term follow-up evaluations are required. Interestingly, we could already show that all patients with treatment-refractory disease included in this analysis were positive for CTCs in the present study. In addition, a strong correlation was found between the presence of CTCs and more advanced clinical stages of GCTs. In a much smaller cohort study, Hautkappe and colleagues previously reported that AFP-and/or bHCG-mRNA detection in peripheral blood of patients with testicular GCTs was associated with the tumor stage (13) . Thus, the significance of CTC detection as complementary biomarker for the identification of patients with high risk of recurrence deserves further attention, including further studies on monitoring of patients with GCTs during chemotherapy and surveillance.
Nonseminomatous tumors tend to be more aggressive and are more prone to metastasize than seminomatous tumors. In this study, CTCs were more frequently found in patients with nonseminomatous than in seminomatous tumors, especially in those with higher percentages of yolk sac and teratoma components. Teratomas and yolk sac tumors have been reported as the most common types of tumors observed in patients with late relapses (34) (35) (36) . Teratomas are not producing common tumor markers such as AFP, bHCG, or LDH. Therefore, evaluation of CTCs might be of special value to detect metastasis or relapse in patients suffering from teratomas. In several studies, the presence of predominantly embryonal carcinoma components has been reported as a factor for poor prognosis (35, (37) (38) (39) . Hautkappe and colleagues detected AFP-and/or bHCG-mRNAs mostly in patients with embryonal carcinomas (13) . In the current study, a strong correlation between the presence of CTCs and a higher percentage (!50%) of embryonal carcinoma component within primary tumors was only found in blood samples analyzed with the CellSearch system, suggesting that this approach might be particularly useful to detect CTCs derived from embryonal carcinomas expressing both EpCAM and one of the detected keratins. Concentrations of AFP, bHCG, and LDH in the serum represent standard tumor markers in GCTs, but only 10% to 60% (nonseminomatous tumors), 10% to 40%, and 40% to 60% of patients, respectively, have elevated concentrations at primary diagnosis (40) . In the present study, CTCs were significantly associated with elevated serum concentrations of AFP, bHCG, and LDH. Higher levels of serum tumor markers after orchiectomy are associated with worse outcome in metastasized nonseminoma (41) . An association between elevated serum tumor markers and the presence of CTCs might indicate a prognostic significance of CTCs. However, CTCs were found also in 4 marker-negative patients, suggesting that determination of CTCs might help minimize the diagnostic gap of conventional tumor markers.
To the best of our knowledge, this is the first study investigating intraoperatively collected blood from the testicular vein of patients with GCTs. The testicular vein carries deoxygenated blood from testis to the inferior vena cava or one of its tributaries and might be the first path of hematogenous tumor cell spread in GCTs (42) . Our results seem to support this hypothesis. Of note, we observed very high numbers of tumor cells of up to 120 per 1 Â 10 6 MNCs in TVB. In the testicular vein, the CTC yield was higher than in peripheral blood, which is similar to the gradients observed in breast and colorectal cancers, where significantly more CTCs could be detected in the central venous blood or the mesenteric vein, respectively (43, 44) . In more than half of patients with GCTs, clusters of 3 to 7 tumor cells were observed, which was much more frequent than in peripheral blood (20%). These findings suggest that a high number of isolated and clustered CTCs is shed from the primary tumor into the local blood stream, and during the circulation, CTCs may undergo anoikis or they might be filtered in the lungs (or other organs), which may cause the observed gradient between TVB and peripheral blood.
Further studies with longer follow-up periods are needed to evaluate the association of CTCs with outcome and in particular survival of patients with GCTs. Molecular characterization of CTCs might help improve our knowledge about metastasis formation (45, 46) and may serve as a "liquid biopsy" assessing potential targets for therapy (e.g., CD30 or glypican-3; refs. [47] [48] [49] or gene mutations relevant to targeted therapy (e.g., c-KIT or BRAF; ref. 50) . Sequential blood analyses during therapy may also hold the promise to gain insights into drug resistance in individual patients. Thus, the present work opens a new avenue to personalized medicine in patients with GCT.
Disclosure of Potential Conflicts of Interest
K. Pantel is a consultant/advisory board member for Janssen and Veridex. No potential conflicts of interest were disclosed by the other authors.
